Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase I/II pilot study of ApoGraft for prevention of acute graft-versus-host disease
MOH_2017-11-09_001873Phase 2Recruiting
- Sponsor
- Select Biotherapeutics
- Start
- Sep 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ApoGraft in Acute Graft-Versus-Host Disease (aGvHD) (4 cohorts), sponsored by Select Biotherapeutics. Primary endpoints: Safety and Proof of concept for prevention of acute graft-versus-host disease. Started Sep 2016; status: recruiting.
02
Drugs
ApoGraft
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on MOH_2017-11-09_001873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-09_001873.